DocWire News Editors

DocwireNews

Access to pain medications has led to the current opioid epidemic. A risk management program reconsidered utilization management to limit inappropriate opioid use and to encourage alignment with the Centers for Disease Control and Prevention (CDC) prescribing guidelines for opioids. This includes a set maximum days&rsquo; supply per fill of new prescriptions, restrictions on frequency of new fills and refills, and morphine equivalent dose (MED) limits depending on whether prescriptions were for new starts or current use.Researchers evaluated the impact of utilization management strategies that were put into place by a large national pharmacy benefits manager. The results of the study were presented at the AMCP Annual Meeting during a poster session titled &ldquo;Impact of Utilization Management Edits on Short-Acting Opioid Use and Prescribing Guideline Compliance.&rdquo;This pre&ndash;post analysis used pharmacy claims data for the two months preceding and five months following the July 1, 2017, implementation of this program. They included any claims for opioid medications during this time and compared clients who accepted the short-acting opioid utilization management edits and those who did not. The primary endpoints of the study were compliance with a 50 mg MED limit and fewer than seven days&rsquo; supply of opioids for members who were new to treatment, or a 90 mg MED limit for treatment-experienced members.The analysis included 611,705 pharmacy claims for 6,122,592 members enrolled in plans that implemented these utilization management edits and 1,388,746 claims for 7,655,947 members that did not.The odds of an opioid prescription for a new treatment member being within the CDC recommended 50 mg MED limit was higher for those who implemented utilization management edits (odds ratio [OR], 3.05; 95% CI, 2.99-3.11) than for those who were not (OR, 1.16; 95% CI 1.15-1.18). This was associated with 16.39% and 2.66%, respectively, improved compliance in each cohort. For new treatment members, the odds of an opioid prescription being within a seven days&rsquo; supply was higher for those in the utilization management edits cohort (OR, 1.29; 95% CI 1.26-1.31) than for those who were not (OR, 0.80; 95% CI 0.79-0.82). This was associated with a 3.37% improvement and 3.72% decrease, respectively, in compliance in each cohort.Treatment-experienced members who were in the utilization management edits cohort were more likely to fill a prescription for less than 90 mg MED (OR, 1.74; 95% CI 1.69-1.80) than those who were not (OR, 1.08; 95% CI 1.06-1.10). This was associated with 3.23% and 0.47%, respectively, improved compliance in each cohort.&ldquo;Clients that implemented utilization management edits had a higher proportion of claims that were compliant with CDC guidelines than clients that did not enact [these],&rdquo; the researchers concluded.The study was sponsored by OptumRx.Chiu C, Ursan I, Fensterheim L, Repp A, Calabrese D, Marks A. Impact of Utilization Management Edits on Short-Acting Opioid Use and Prescribing Guideline Compliance. Abstract F5. Presented at the AMCP Managed Care &amp; Specialty Pharmacy Annual Meeting, April 23-26; Boston, MA.

Bradley Marder, MD

Joel M. Topf, MD, FACP

Gout Studies: Transplant Waitlisting and Bone Erosion

NKF Spring Clinical Meetings 2025

Jayme Locke, MD, MPH

The Promise of Xenotransplantation

Leah Lawrence

Real-World Data Backs Invasive DFS as Surrogate Endpoint for OS in EBC

HR Breast Cancer

Latest News

Restrictions on Opioid Prescribing Result in Outcomes Aligned with CDC Guidelines

AMCP 2018

Access to pain medications has led to the current opioid epidemic. A risk management program reconsidered utilization management to limit inappropriate opioid use and to ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe